Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025
Rhea-AI Summary
Biofrontera (Nasdaq: BFRI) will report results for the three and nine months ended September 30, 2025 after U.S. market close on Wednesday, November 12, 2025. The company will host a conference call and webcast to discuss the results, provide a business update and answer questions on Thursday, November 13, 2025 at 10:00am ET.
Conference call numbers and an investor webcast will be available for live participation. Biofrontera commercializes the drug-device combination Ameluz with the RhodoLED lamp series for photodynamic therapy (PDT) and is conducting clinical trials to expand indications to non-melanoma skin cancers and moderate to severe acne.
Positive
- None.
Negative
- None.
WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on Wednesday, November 12, 2025. The company will host a conference call on Thursday, November 13 at 10:00am Eastern Time to discuss those results, provide a business update and answer questions.
Conference Call and Webcast Information
| Event: | Biofrontera Inc. Third Quarter 2025 Financial Results and Business Update Conference Call |
| Date: | Thursday, November 13, 2025 |
| Time: | 10:00am ET |
| Conference Call: | 1-877-877-1275 (U.S.) 1-412-858-5202 (international) |
| Webcast: | Webcast - Biofrontera Inc. 3Q25 Results Conference Call |
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.
Investor Relations
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
FAQ
When will Biofrontera (BFRI) release third quarter 2025 financial results?
What time is the Biofrontera (BFRI) Q3 2025 conference call?
How can investors access the Biofrontera (BFRI) Q3 2025 webcast and call?
What will Biofrontera (BFRI) discuss on the November 13, 2025 call?
What products does Biofrontera (BFRI) commercialize that relate to the update?
